NasdaqGS - Nasdaq Real Time Price • USD
Insulet Corporation (PODD)
As of 10:11 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 18 | 18 |
| Avg. Estimate | 0.38 | 0.56 | 2.99 | 3.78 |
| Low Estimate | 0.28 | 0.43 | 2.62 | 3.21 |
| High Estimate | 0.61 | 0.74 | 3.3 | 4.15 |
| Year Ago EPS | 0.23 | 0.38 | 2.75 | 2.99 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 17 | 22 | 21 |
| Avg. Estimate | 424.05M | 457.76M | 1.96B | 2.33B |
| Low Estimate | 419.8M | 442M | 1.94B | 2.28B |
| High Estimate | 434M | 475M | 1.99B | 2.42B |
| Year Ago Sales | 358.1M | 384.95M | 1.7B | 1.96B |
| Sales Growth (year/est) | 18.40% | 18.90% | 15.60% | 18.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.11 | 0.26 | 0.4 | 0.66 |
| EPS Actual | 0.23 | 0.38 | 0.71 | 1.4 |
| Difference | 0.12 | 0.12 | 0.31 | 0.74 |
| Surprise % | 109.10% | 46.20% | 77.50% | 112.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.38 | 0.56 | 2.99 | 3.78 |
| 7 Days Ago | 0.38 | 0.56 | 2.99 | 3.79 |
| 30 Days Ago | 0.38 | 0.56 | 2.99 | 3.79 |
| 60 Days Ago | 0.43 | 0.51 | 2.45 | 3.27 |
| 90 Days Ago | 0.43 | 0.51 | 2.45 | 3.27 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | PODD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 65.20% | -- | -- | 1.30% |
| Next Qtr. | 47.40% | -- | -- | 10.60% |
| Current Year | 8.70% | -- | -- | 5.10% |
| Next Year | 26.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 18.10% | -- | -- | 11.21% |
| Past 5 Years (per annum) | 75.15% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Equal-Weight to Equal-Weight | 2/26/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/23/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/23/2024 |
| Maintains | Stifel: Hold to Hold | 2/5/2024 |
| Upgrade | Baird: Neutral to Outperform | 12/21/2023 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 12/4/2023 |
Related Tickers
DXCM DexCom, Inc.
134.84
+2.52%
TNDM Tandem Diabetes Care, Inc.
34.20
+7.78%
NARI Inari Medical, Inc.
37.35
-1.53%
INSP Inspire Medical Systems, Inc.
229.31
+1.82%
MASI Masimo Corporation
136.37
+1.53%
EW Edwards Lifesciences Corporation
87.29
+0.37%
ALGN Align Technology, Inc.
306.73
+1.96%
PEN Penumbra, Inc.
206.01
+1.48%
BIO Bio-Rad Laboratories, Inc.
292.81
+4.52%
QDEL QuidelOrtho Corporation
40.55
+3.75%